Compare GE Vernova Inc (GEV) vs Novavax Inc (NVAX) Price & Performance

GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net margin, though valuation metrics appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent news highlights the company securing the first US construction permit for its BWRX-300 small modular reactor and benefiting from AI-driven power demand growth.

GEV presents growth potential from its $176 billion backlog and AI infrastructure demand, but faces valuation concerns and execution risks in its wind power segment. Analyst consensus remains strongly bullish with 75.86% buy ratings and $1,270 price target, representing 27% upside from current levels. Key risks include competitive pressures and the challenge of maintaining current premium valuation multiples.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.